OBJECTIVE: To understand factors guiding overactive bladder (OAB) therapy selection and experience with combination therapy (antimuscarinics and beta-3 agonists). METHODS: Cross-sectional surveys of OAB patients and OAB-treating physicians in the USA were conducted. Patients receiving monotherapy with antimuscarinics were categorized by OAB treatment history: monotherapy only; third-line procedures (e.g., onabotulinumtoxinA injections) and combination therapy; third-line therapy only; and combination therapy only. The patient survey assessed therapy choice drivers and barriers, treatment satisfaction and sociodemographic/clinical characteristics. The physician survey assessed drivers of and barriers to OAB treatment choices. RESULTS: Of 200 patients, 86.5% reported involvement in treatment decision-making; doctor's recommendation was the most frequently considered factor (84.4%). Most patients (71%) were unaware of combination therapy. The primary reason why those patients aware of combination therapy had not used it (N = 43/200; 21%) was physician recommendation of other treatments (69.8%). For physicians (N = 50), the most frequently considered factors when prescribing OAB treatment were effectiveness (92.0%) and side effects (84.0%); 70% prescribed combination therapy, primarily for symptom severity (82.9%). The main reasons for not prescribing combination therapy were cost/insurance coverage (80%) and lack of information (53.3%). CONCLUSIONS: Shared decision-making guided treatment decisions; the main considerations were treatment safety and efficacy.
OBJECTIVE: To understand factors guiding overactive bladder (OAB) therapy selection and experience with combination therapy (antimuscarinics and beta-3 agonists). METHODS: Cross-sectional surveys of OAB patients and OAB-treating physicians in the USA were conducted. Patients receiving monotherapy with antimuscarinics were categorized by OAB treatment history: monotherapy only; third-line procedures (e.g., onabotulinumtoxinA injections) and combination therapy; third-line therapy only; and combination therapy only. The patient survey assessed therapy choice drivers and barriers, treatment satisfaction and sociodemographic/clinical characteristics. The physician survey assessed drivers of and barriers to OAB treatment choices. RESULTS: Of 200 patients, 86.5% reported involvement in treatment decision-making; doctor's recommendation was the most frequently considered factor (84.4%). Most patients (71%) were unaware of combination therapy. The primary reason why those patients aware of combination therapy had not used it (N = 43/200; 21%) was physician recommendation of other treatments (69.8%). For physicians (N = 50), the most frequently considered factors when prescribing OAB treatment were effectiveness (92.0%) and side effects (84.0%); 70% prescribed combination therapy, primarily for symptom severity (82.9%). The main reasons for not prescribing combination therapy were cost/insurance coverage (80%) and lack of information (53.3%). CONCLUSIONS: Shared decision-making guided treatment decisions; the main considerations were treatment safety and efficacy.
Authors: Paul Abrams; Karl-Erik Andersson; Apostolos Apostolidis; Lori Birder; Donna Bliss; Linda Brubaker; Linda Cardozo; David Castro-Diaz; P R O'Connell; Alan Cottenden; Nikki Cotterill; Dirk de Ridder; Roger Dmochowski; Chantal Dumoulin; Mandy Fader; Christopher Fry; Howard Goldman; Philip Hanno; Yukio Homma; Vik Khullar; Chris Maher; Ian Milsom; Diane Newman; Rien J M Nijman; Kevin Rademakers; Dudley Robinson; Peter Rosier; Eric Rovner; Stefano Salvatore; Masayuki Takeda; Adrian Wagg; Todd Wagner; Alan Wein Journal: Neurourol Urodyn Date: 2018-08-14 Impact factor: 2.696
Authors: Muhammet F Kilinc; Omer G Doluoglu; Yildiray Yildiz; Cem N Yuceturk; Ahmet M Hascicek Journal: Neurourol Urodyn Date: 2019-03-14 Impact factor: 2.696
Authors: Vernon F Schabert; Tamara Bavendam; Erica L Goldberg; Jeffrey N Trocio; Linda Brubaker Journal: Am J Manag Care Date: 2009-03 Impact factor: 2.229
Authors: Leslie M Rickey; Melissa L Constantine; Emily S Lukacz; Jerry L Lowder; Diane K Newman; Linda Brubaker; Kyle Rudser; Cora E Lewis; Lisa K Low; Mary H Palmer; Todd Rockwood Journal: J Urol Date: 2020-12-22 Impact factor: 7.450
Authors: James Jiang; Dattatraya Patil; Elizabeth J Traore; Jessica Hammett; Christopher P Filson Journal: Urology Date: 2020-05-11 Impact factor: 2.649